b
r
c
outbreak
sever
viru
infect
potenti
caus
global
pandem
increas
mani
instanc
outbreak
newli
emerg
sar
coronaviru
reemerg
ebola
viru
zika
viru
zoonot
avian
influenza
viru
infect
absenc
target
vaccin
pathogenspecif
antivir
broadspectrum
antivir
would
function
limit
viru
spread
given
direct
antivir
effect
type
interferon
ifn
inhibit
replic
dna
rna
virus
differ
stage
replic
cycl
effect
type
ifn
activ
immun
cell
popul
clear
viru
infect
present
ideal
candid
broadspectrum
antivir
interferon
ifn
critic
effector
innat
adapt
immun
respons
associ
develop
immun
cell
popul
activ
respond
pathogen
cancer
insult
ifn
classifi
accord
receptor
signal
fig
type
ifn
signal
receptor
ifnar
one
three
major
class
ifn
two
type
ii
ifn
type
iii
ifn
type
ifn
discov
effect
inhibit
viru
replic
sinc
shown
exert
critic
effect
develop
activ
immun
cell
subset
given
antivir
immunomodulatori
effect
type
ifn
alon
combin
therapi
examin
clinic
varieti
chronic
acut
viral
infect
review
highlight
antivir
immunomodulatori
effect
type
ifn
mechan
virus
inhibit
evad
host
type
ifn
respons
describ
recent
therapeut
applic
recombin
type
ifn
treatment
viral
infect
type
ifn
induc
follow
detect
pathogenassoci
molecular
pattern
pamp
damagedangerassoci
molecular
pattern
damp
innat
pattern
recognit
receptor
prr
express
immun
nonimmun
cell
prr
compris
tolllik
receptor
tlr
ctype
lectin
receptor
clr
retino
acidinduc
gene
rigi
like
receptor
rlr
nucleotidebind
oligomer
domain
nod
like
receptor
nlr
receptor
alr
cyclic
gmpamp
synthas
cga
togeth
bind
divers
rang
extracellular
endosom
pamp
damp
fig
prr
signal
result
express
type
ifn
proinflammatori
cytokin
mediat
three
essenti
transcript
factor
ifn
regulatori
factor
irf
nuclear
virusinduc
express
upregul
format
enhanceosom
compris
cjun
promot
induct
type
ifn
provid
first
line
defens
mani
divers
pathogen
inde
ifn
dysregul
lead
increas
viru
suscept
rigi
mice
produc
lower
level
type
ifn
suscept
infect
rna
virus
includ
japanes
enceph
viru
jev
encephalomyocard
viru
emcv
west
nile
viru
wnv
type
ifn
bind
cognat
transmembran
receptor
ifnar
compris
receptor
alpha
chain
receptor
beta
chain
receptor
bind
lead
activ
multipl
intracellular
signal
cascad
fig
best
known
activ
canon
janu
kinas
jak
signal
transduc
activ
transcript
stat
pathway
wherebi
ifnarassoci
particip
recruit
stat
ifnar
subsequ
phosphorylationactiv
form
homoor
heterodim
unlik
stat
dimer
heterodim
also
bind
form
ifnstimul
gene
isg
factor
complex
nucleu
bind
ifnsensit
respons
element
isr
stat
dimer
bind
activ
sequenc
ga
element
initi
transcript
isg
sever
noncanon
pathway
also
activ
type
ifn
includ
mitogenactiv
protein
kinas
mapk
signal
pathway
modul
histon
modif
earli
gene
express
phosphoinositid
protein
kinas
b
akt
pathway
regul
activ
protein
synthesi
capdepend
mrna
translat
saleiro
et
al
issu
human
ifninduc
transcript
translat
regul
isg
result
express
gene
contribut
cellular
process
includ
metabol
surviv
migrat
activ
importantli
innat
host
defens
viral
infect
notabl
mani
isg
identifi
function
interfer
differ
stage
viral
replic
transmiss
tabl
interestingli
vitro
studi
examin
effect
coxsackieviru
infect
identifi
novel
function
regul
glucos
metabol
mediat
activ
signal
pathway
import
induct
rapid
antivir
respons
type
ifn
divers
effect
immun
system
beyond
induct
antivir
isg
rang
regul
leukocyt
develop
differenti
immun
cell
recruit
activ
earliest
stage
leukocyt
develop
signal
shown
affect
renew
prolifer
hematopoiet
stem
cell
hsc
mice
enhanc
prolifer
dormant
hsc
aktphosphoryl
depend
manner
moreov
chronic
signal
lead
hsc
exhaust
result
reduct
number
quiescent
hsc
bone
marrow
result
hsc
lack
neg
regul
type
ifn
signal
fail
outcompet
hsc
competit
repopul
assay
type
ifn
also
regul
express
chemokin
cell
adhes
receptor
therebi
affect
traffick
differ
immun
cell
popul
signal
upregul
chemokin
cc
motif
ligand
ccl
chemokin
cxc
motif
ligand
cxcl
cluster
differenti
cd
downregul
express
briefli
chemoattract
monocyt
chemoattract
cell
also
recruit
memori
cell
chemoattract
monocyt
macrophag
recruit
neutrophil
express
promot
retent
lymphocyt
lymph
node
inhibit
sphingosin
therebi
promot
antigen
present
lymphocyt
activ
addit
influenc
chemokin
express
type
ifn
also
regul
surviv
activ
innat
adapt
immun
cell
although
type
ifn
inhibit
recruit
neutrophil
suppress
express
shown
promot
neutrophil
surviv
induc
express
cellular
inhibitor
apoptosi
via
nk
cell
type
ifn
signal
enhanc
product
cell
surviv
cytotox
tumor
cell
virusinfect
cell
upregul
fa
ligand
fasl
express
moreov
type
ifn
signal
macrophag
import
phagocytosi
nitric
oxid
synthas
express
contribut
clearanc
pathogen
tumor
cell
damag
tissu
monocyt
express
high
level
ifnar
cell
surfac
presenc
granulocytemacrophag
colonystimul
factor
gmcsf
rapidli
differenti
dc
capabl
present
antigen
prime
helper
h
cell
activ
cell
type
ifn
signal
convent
dc
cdc
direct
h
immun
cell
activ
boost
product
presenc
pamp
enhanc
express
major
histocompat
complex
mhc
class
mhc
class
ii
costimulatori
factor
plasmacytoid
dc
pdc
also
produc
consider
presenc
pamp
compar
leukocyt
due
high
level
constitut
express
type
ifn
regul
effector
memori
cell
review
cytotox
cell
upregul
perforin
granzym
b
express
curtsing
et
al
show
absenc
signal
cell
fail
upregul
perforin
granzym
b
express
even
presenc
antigen
costimul
therefor
may
provid
necessari
third
signal
cell
effector
function
context
viral
infect
type
ifn
also
critic
cell
clonal
expans
memori
format
contribut
eomesodermin
eom
tbox
transcript
factor
tbet
express
use
ifnar
cell
le
bon
et
al
show
intact
type
ifn
signal
affect
abil
cell
provid
b
cell
help
well
format
antigenspecif
antibodi
respons
regard
cell
subset
type
ifn
downregul
h
h
differenti
inhibit
express
respect
mice
exhibit
defect
b
cell
matur
result
significantli
fewer
circul
immunoglobulin
ig
b
cell
wildtyp
mice
defect
character
reduct
prob
cell
igm
b
cell
popul
bone
marrow
moreov
b
cell
express
significantli
lower
level
igm
wildtyp
b
cell
like
monocyt
b
cell
also
express
high
level
surfac
ifnar
signal
import
b
cell
surviv
activ
type
ifn
signal
upregul
surfac
express
mhc
class
mhc
class
ii
lselectin
b
cell
prime
b
cell
receptor
bcr
activ
express
transit
stage
b
cell
spleen
critic
surviv
develop
furthermor
induc
b
cell
activ
factor
baff
proliferationinduc
ligand
april
express
dc
promot
b
cell
ig
class
switch
virusactiv
pdc
also
direct
antigenspecif
b
cell
differenti
igsecret
plasma
cell
mediat
combin
type
ifn
signal
given
effect
ifninduc
antivir
respons
limit
infect
viral
replic
larg
cellindepend
manner
irrespect
viru
virus
develop
differ
mechan
inhibit
type
ifn
induct
signal
activ
antivir
isg
tabl
virus
may
encod
genom
multipl
differ
protein
target
differ
facet
type
ifninduc
antivir
respons
singl
multifunct
protein
herp
simplex
viru
hsv
encod
sever
protein
direct
differ
ifninduc
target
wherea
influenza
viru
iav
encod
multifunct
viral
protein
capac
interfer
multipl
host
pathway
protein
involv
antivir
respons
receptor
activ
lead
type
ifn
product
bind
pamp
damp
host
prr
tlr
clr
rlr
nlr
alr
cga
induc
signal
cascad
activ
result
product
type
proinflammatori
cytokin
newli
emerg
reemerg
viru
infect
pose
seriou
threat
global
health
fig
absenc
target
vaccin
newli
emerg
viru
infect
suffici
vaccin
avail
reemerg
viru
infect
obviou
need
direct
antivir
deploy
pandem
virus
mutat
becom
resist
pathogenspecifc
antivir
necessit
develop
broadspectrum
pleiotrop
antivir
type
ifn
prototyp
candid
broadspectrum
antivir
specif
rapid
induct
respons
viru
infect
pleiotrop
natur
effect
inhibit
differ
stage
viral
replic
cycl
effect
activ
immun
cell
clear
viru
infect
surprisingli
therefor
mention
virus
evolv
p
bind
inhibit
nuclear
transloc
phosphoryl
stat
protein
isr
ga
activ
also
inhibit
activ
induct
rotaviru
rv
enhanc
degrad
inhibit
type
ifn
induct
also
inhibit
nfb
activ
continu
next
page
evad
ifn
respons
specif
critic
host
immun
respons
infect
howev
given
pleiotrop
natur
antivir
effect
ifn
virustarget
inhibit
element
may
still
permit
partial
effect
ifn
respons
date
howev
type
ifn
seen
limit
clinic
use
treatment
acut
chronic
infect
pegyl
recombin
peginf
combin
ribavirin
nucleosid
inhibitor
viral
rna
synthesi
remain
standard
care
treatment
chronic
hepat
c
viru
hcv
infect
jurisdict
direct
antivir
agent
daa
unavail
type
ifn
first
approv
singleag
therapeut
use
context
hcv
infect
major
limit
clinic
use
type
ifn
hcv
preval
advers
event
common
advers
event
includ
fatigu
headach
pyrexia
rigor
myalgia
nausea
abdomin
pain
anxieti
depress
psychosi
insomnia
seriou
advers
event
includ
neutropenia
thrombocytopenia
hyperand
hypothyroid
pancreat
type
diabet
mellitu
irrevers
pulmonari
hypertens
notabl
advers
advent
associ
sustain
ifn
treatment
pegyl
recombin
ifn
improv
pharmacokinet
allow
longer
dose
interv
clinic
efficaci
ifn
therapi
determin
measur
serum
hcv
rna
level
sustain
virolog
respons
svr
defin
undetect
hcv
rna
level
week
follow
complet
ifn
therapi
patient
infect
hcv
genotyp
g
exhibit
svr
rate
enhanc
host
mrna
degrad
inhibit
mrna
translat
suppress
type
ifn
express
also
inhibit
activ
phosphoryl
inhibit
phosphoryl
nuclear
transloc
bind
inhibit
nuclear
transloc
isg
express
vaccinia
viru
vacv
bind
dsrna
inhibit
pkr
rnasel
activ
also
inhibit
activ
induct
inhibit
pkr
activ
bind
type
ifn
inhibit
ifn
signal
west
nile
viru
wnv
inhibit
type
ifninduc
phosphoryl
isr
activ
inhibit
phosphoryl
isg
express
comparison
svr
rate
approxim
patient
infect
hcv
respect
furthermor
patient
hcv
infect
exhibit
rapid
virolog
respons
rvr
defin
undetect
serum
hcv
rna
week
treatment
like
achiev
svr
addit
rvr
predic
svr
includ
low
express
suppressor
cytokin
signal
mrna
protein
liver
wherea
elev
express
polymorph
gene
promot
region
associ
nonrespons
lack
variat
gene
sequenc
encod
pkrbind
domain
within
hcv
may
contribut
increas
resist
peginf
ribavirin
combin
therapi
peginf
also
shown
therapeut
efficaci
patient
chronic
hepat
b
viru
hbv
infect
evidenc
seroconvers
hepat
b
eantigen
hbeag
posit
activ
hbv
replic
hbeag
neg
detect
level
antihb
antibodi
studi
conduct
keat
et
al
hbv
infect
patient
treat
peginf
achiev
seroconvers
clear
viru
one
year
follow
onset
treatment
studi
inact
hbv
detect
anoth
treat
patient
singl
patient
case
studi
chronic
hepat
e
viru
hev
infect
weekli
peginf
treatment
result
decreas
serum
hev
rna
week
complet
virolog
respons
week
patient
serum
hev
rna
remain
undetect
month
svr
seen
anoth
patient
chronic
hev
infect
follow
peginf
treatment
undetect
serum
hev
rna
week
persist
month
cessat
peginf
treatment
peginf
treatment
induc
isg
transcript
clearanc
hev
infect
human
mice
apart
clinic
use
chronic
viru
infect
littl
consider
given
applic
type
ifn
sever
acut
viru
infect
novemb
august
case
sever
acut
respiratori
syndrom
coronoaviru
sarscov
infect
report
worldwid
result
death
absenc
vaccin
approv
daa
treatment
limit
corticosteroid
ribavirin
support
care
ifn
synthet
engin
posit
along
amino
acid
protein
frequent
repres
amino
acid
among
subtyp
present
result
vitro
vivo
studi
identifi
ifn
consist
exhibit
superior
antivir
potenc
compar
subtyp
attribut
higher
bind
affin
ifnar
sar
outbreak
pilot
clinic
studi
toronto
canada
evid
provid
treatment
ifn
associ
rapid
resolut
radiograph
lung
abnorm
better
oxygen
satur
compar
infect
patient
receiv
corticosteroid
ifntreat
patient
exhibit
lower
level
creatin
kinas
rapid
return
lactat
dehyrogenas
level
normal
indic
improv
sarsassoci
lung
parenchym
diseas
notabl
given
short
treatment
time
day
patient
toler
ifn
treatment
well
minim
advers
event
exacerb
virusassoci
symptom
singl
clinic
advers
event
report
fever
like
associ
underli
diseas
subsequ
vitro
studi
use
human
bronchial
epitheli
cell
reveal
type
ifn
treatment
directli
inhibit
sarscov
replic
overrid
inhibitori
effect
viral
encod
factor
nonhuman
primat
studi
administr
ifn
prior
sarscov
infect
cynomolgu
macaqu
limit
viral
replic
pulmonari
damag
recent
unpreced
ebola
viru
ebov
diseas
outbreak
west
africa
approv
therapi
vaccin
avail
earlier
studi
nonhuman
primat
provid
evid
treatment
reduc
blood
viremia
prolong
surviv
infect
anim
despit
viral
encod
ifn
inhibitori
factor
moreov
combin
monoclon
antibodi
cocktail
direct
ebov
glycoprotein
zmab
adenovirusvector
therapi
extend
treatment
window
postinfect
nonhuman
primat
suppress
viremia
lead
surviv
robust
immun
respons
use
transcriptioncompet
viruslik
particl
trvlp
model
ebov
zair
infect
vitro
requir
level
contain
mccarthi
et
al
screen
panel
candid
antivir
drug
assess
abil
suppress
viral
replic
human
cell
along
estrogen
receptor
modul
toremifen
number
viral
polymeras
inhibitor
lamivudin
zidovudin
tenofovir
favipiravir
inhibit
trvlp
replic
administ
h
postinfect
notabl
exhibit
potent
antivir
activ
twoand
threedrug
combin
test
use
vitro
model
twoand
threedrug
combin
potent
inhibit
ebov
trvlp
replic
lamivudin
lamivudin
zidovudin
respect
moreov
drug
combin
inhibit
infecti
recombin
ebov
zair
replic
cell
given
superior
antivir
potenc
trvlp
studi
use
ebov
zair
administ
patient
infect
ebov
proofofconcept
singl
arm
clinic
studi
guinea
ebov
diseas
outbreak
compar
ebov
infect
patient
receiv
standard
support
care
treatment
facil
treatment
associ
faster
viral
clearanc
blood
earlier
resolut
diseas
symptom
better
surviv
patient
toler
ifn
treatment
well
exacerb
diseas
symptom
preliminari
clinic
find
provid
rational
clinic
evalu
treatment
ebov
infect
type
ifn
also
shown
inhibit
acut
influenza
viru
iav
infect
vitro
primari
human
lung
explant
ifn
inhibit
avian
pandem
iav
replic
upregul
express
sever
antivir
isg
pkr
oa
treatment
iavinfect
human
lung
cell
inhibit
viral
replic
dosedepend
manner
context
anoth
acut
viru
infect
west
nile
viru
type
ifn
shown
increas
incorpor
microrna
mirna
extracellular
vesicl
cell
enrich
mirna
regul
gene
involv
antivir
proinflammatori
respons
oral
administ
low
molecular
weight
agonist
shown
mimic
action
inhibit
hcv
hbv
infect
vitro
abl
induc
jakstat
signal
upregul
isg
express
adenovirusvector
longlast
antivir
activ
protect
mice
hamster
nonhuman
primat
anim
model
enteroviru
ev
ebov
chikungunya
viru
chikv
rift
valley
fever
viru
rvfv
infect
singl
dose
adenovirusvector
given
intranas
within
h
postrvfv
challeng
significantli
reduc
viral
load
serum
liver
spleen
hamster
administ
prophylact
day
h
prior
chikv
challeng
mice
reduc
chikv
viral
titer
furthermor
administr
h
h
postleth
infect
mice
result
full
partial
protect
respect
view
togeth
vivo
studi
provid
rational
evalu
prophylact
therapeut
effect
adenovirusvector
treatment
sever
acut
viru
infect
vaccin
andor
approv
antivir
agent
unavail
preced
serv
illustr
pleiotrop
natur
type
ifn
inhibit
viru
replic
irrespect
viru
viru
outbreak
pose
seriou
threat
global
health
exemplifi
recent
outbreak
sar
cov
avian
influenza
zika
viru
wnv
ebov
absenc
vaccin
target
newli
emerg
reemerg
viru
antivir
drug
serv
limit
viral
spread
virus
mutat
specif
evad
pathogenspecif
antivir
case
point
emerg
tamifluresist
influenza
strain
prefer
strategi
limit
viru
outbreak
would
deploy
broadspectrum
antivir
agent
would
exhibit
pleiotrop
effect
includ
invok
metabol
event
import
induct
rapid
antivir
respons
target
differ
stage
viru
replic
cycl
also
invok
robust
immun
respons
viru
regardless
viru
type
ifn
present
ideal
broadspectrum
antivir
candid
limit
clinic
studi
demonstr
therapeut
effect
sever
acut
viru
infect
evalu
warrant
